Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Rises By 77.9%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 112,600 shares, an increase of 77.9% from the February 29th total of 63,300 shares. Based on an average trading volume of 114,500 shares, the short-interest ratio is currently 1.0 days. Currently, 0.9% of the shares of the company are short sold.

Cyclo Therapeutics Trading Down 0.7 %

Shares of NASDAQ:CYTH traded down $0.01 during trading on Thursday, reaching $1.39. 30,476 shares of the stock were exchanged, compared to its average volume of 101,754. Cyclo Therapeutics has a 12 month low of $0.67 and a 12 month high of $2.57. The firm has a market cap of $39.92 million, a PE ratio of -1.07 and a beta of -0.14. The stock has a 50-day moving average price of $1.67 and a 200-day moving average price of $1.48.

Institutional Investors Weigh In On Cyclo Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Cyclo Therapeutics by 26.0% in the fourth quarter. Vanguard Group Inc. now owns 355,223 shares of the company’s stock valued at $565,000 after buying an additional 73,196 shares during the period. Founders Fund V Management LLC bought a new stake in shares of Cyclo Therapeutics in the fourth quarter valued at approximately $764,000. Founders Fund VI Management LLC bought a new stake in shares of Cyclo Therapeutics in the fourth quarter valued at approximately $175,000. Citadel Advisors LLC boosted its stake in shares of Cyclo Therapeutics by 282.1% in the fourth quarter. Citadel Advisors LLC now owns 54,018 shares of the company’s stock valued at $86,000 after buying an additional 39,881 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Cyclo Therapeutics in the second quarter valued at approximately $28,000. 68.55% of the stock is currently owned by institutional investors.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.